Hypermarcas (OTCMKTS:HYPMY) Stock Falls 8.8% – Should You Sell?

Hypermarcas (OTCMKTS:HYPMY) traded down 8.8% during mid-day trading on Wednesday. The stock traded as low as $3.92 and last traded at $4.2142. 4,018 shares were traded during mid-day trading, a decline of 79% from the average session volume of 19,450 shares. The stock had previously closed at $4.62.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group upgraded shares of Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy”.

Hypermarcas Stock Performance

The stock has a market capitalization of $2.97 billion, a P/E ratio of 8.43 and a beta of 0.71. The company has a quick ratio of 1.26, a current ratio of 1.86 and a debt-to-equity ratio of 0.50. The business has a fifty day moving average price of $4.30 and a 200-day moving average price of $4.32.

Hypermarcas (OTCMKTS:HYPMY) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. On average, sell-side analysts expect that Hypermarcas will post 0.53 EPS for the current year.

About Hypermarcas

Hypermarcas SA was a Brazilian consumer health and pharmaceutical company that developed, manufactured and marketed branded products for healthcare, personal care and consumer markets. Its portfolio historically included over-the-counter medicines, prescription products, vitamins, toiletries, cosmetics and other household or personal-care brands.

The company expanded through acquisitions and operated primarily in Brazil, building a broad portfolio of locally recognized brands. In the mid-2010s, Hypermarcas began divesting its non-pharmaceutical businesses to concentrate on healthcare and medicines.